Among Stage I ccRCC patients, those with middle-to-low MAGI3 expression (<261.5 RPKM or H-score ≤ 6) experience a notable decrease in 10-year OS (45.5% vs. 74.6%), PFS (55% vs. 69.8%), and DSS (77.9% vs. 98%) compared to those with high MAGI3 expression (>261.5 RPKM or H-score ≥ 8) (Fig. 1). The gene discussed is MAGI3; the disease is nonpapillary renal cell carcinoma.